FDA Peptide Reclassification 2026: BPC-157 & the 503A List

PCAC July 2026 Review — Seven Peptides at a Glance

Uses listed are the indications under FDA/PCAC compounding review on the dates shown — they are not therapeutic claims. Remy Research supplies research-grade peptides for in-vitro laboratory research use only.

Is BPC-157 FDA Approved?

No. BPC-157 is not an FDA-approved drug, and it never has been. It holds no approved indication in the United States or any other major jurisdiction. The FDA had listed BPC-157 among bulk drug substances that “may present significant safety risks” — the interim Category 2 designation the agency applied to more than a dozen peptides in 2023 — but the nomination was withdrawn in April 2026, moving BPC-157 to the FDA’s separate “nominated but withdrawn” list (the safety-risk record remains). That did not make it compoundable: the FDA’s 503A category list of May 14, 2026 does not place BPC-157 in Category 1, and it is not on the 503A Bulks List. On July 23, 2026 the PCAC voted 8–6, with one abstention, to recommend adding it to that list for ulcerative colitis, against the advice of the FDA’s reviewers (Reuters); the vote is non-binding, and no final FDA action had been published as of October 7, 2026.

Is BPC-157 “banned”? Not through a formal ban. Because it is neither on the compounding-eligible 503A Bulks List nor in Category 1 of the FDA’s interim categories, the FDA does not extend its enforcement-discretion policy to it, and compounding pharmacies that use it carry regulatory risk. The July 2026 PCAC vote was the formal reconsideration of whether BPC-157 should move onto the permitted 503A list — a recommendation that is advisory and non-binding on the FDA.

TB-500, MOTS-c, and KPV are in the same regulatory position: none is FDA-approved, all three had their Category 2 nominations withdrawn in April 2026 (the FDA now lists them among substances nominated but withdrawn, safety-risk record intact), none is in Category 1 or on the 503A Bulks List, and all three were reviewed with BPC-157 on July 23, 2026. The PCAC voted to recommend each of them, against the advice of the FDA’s reviewers: TB-500 and KPV 8–6 with one abstention each, and MOTS-c 7–5 with two abstentions (Reuters; McDermott Will & Schulte).

Category 2 was the FDA designation for bulk substances with identified significant safety risks for compounding use — not on the compounding-eligible list, and not an approval decision. The four peptides here were placed in Category 2 in 2023 and then removed in April 2026 when the nominations were withdrawn, without being placed in Category 1 or on the 503A Bulks List; none is an approved drug in any jurisdiction. This is separate from the research-use lane: the 503A framework governs pharmacy compounding for human prescriptions, while research-grade peptides are supplied for in-vitro laboratory research use only.

What Is the PCAC and Why Does This Meeting Matter?

The Pharmacy Compounding Advisory Committee is a standing FDA advisory body that evaluates active pharmaceutical ingredients (APIs) for inclusion on the 503A Bulks List — the list of bulk drug substances that licensed compounding pharmacies may legally use to prepare medications for individual patients with valid prescriptions. The committee reviews each candidate against four criteria laid out in Section 503A(b)(1)(A)(i) of the Federal Food, Drug, and Cosmetic Act: physical and chemical characterization, safety, evidence of effectiveness, and historical use in compounding.

PCAC outcomes are advisory recommendations to the FDA, not final rulings. A positive vote does not automatically place a peptide on the list. A negative vote does not by itself ban it. If the agency acts on PCAC recommendations, it does so through Federal Register rulemaking — first a proposed rule, then a public comment window, then a final rule. That process has no fixed timeline, and as of October 7, 2026 no final FDA action on the July 2026 votes had been published. Meeting materials and the official agenda are posted on the FDA advisory committee calendar at fda.gov.

The July 2026 meeting matters because its votes are the committee’s advice to the FDA on whether these peptides, after leaving Category 2, should be added to the 503A Bulks List. The compounded-peptide market expanded significantly during the GLP-1 shortage years, and the agency is now tightening the framework. The same regulatory cycle that produced the April 30, 2026 proposed 503B exclusion of semaglutide, tirzepatide, and liraglutide is now reaching the 503A peptide list — with implications for clinics, compounders, and US patients who rely on compounded peptide protocols.

Day 1 — July 23, 2026: BPC-157, TB-500, MOTS-c, KPV

Day 1 covers four peptides framed around tissue repair, regeneration, and metabolic indications. The FDA docket evaluates each compound as the free base and the acetate salt where applicable, because compounders sometimes source one form and substitute the other based on stability or supplier availability.

Ahead of the meeting, the FDA posted substance-specific briefing documents for each Day 1 peptide — BPC-157, TB-500, MOTS-c, and KPV — alongside an introduction and Day 2 packages for Semax, Epitalon, and Emideltide (DSIP). These background packages set out the evidence the committee weighs against the four 503A criteria. The FDA’s reviewers recommended against listing each peptide; the committee’s July 23 votes, reported by Reuters, are given under each peptide below. All are advisory and non-binding.

BPC-157 — Use Under Review: Ulcerative Colitis

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a 15-amino-acid fragment of a protein found in human gastric juice. Preclinical literature, primarily from a small group of laboratories in Croatia, reports effects on angiogenesis, tendon and ligament healing, and gastrointestinal tissue repair. The PCAC docket evaluates the indication of ulcerative colitis, the use with the deepest historical compounding signal.

The evidence picture is contested. A February 3, 2026 STAT News investigation argued the published BPC-157 literature is concentrated in a narrow author network with limited independent replication and minimal controlled human data. A Phase 2 randomized controlled trial registered as NCT07437547 is enrolling, and the NCBI PMC review at PMC12446177 catalogues mechanisms across rodent injury models. As of October 7, 2026, BPC-157 has no approved indication in any jurisdiction. The 503A vote is therefore a question of historical compounding use plus the strength of the available preclinical record, not approved therapeutic status. On July 23 the committee voted 8–6, with one abstention, to recommend adding BPC-157 for ulcerative colitis.

TB-500 — Use Under Review: Wound Healing

TB-500 is defined by the FDA and the anti-doping literature (Ho et al. 2012; Esposito et al. 2012) as Ac-LKKTETQ, a 7-amino-acid fragment of Thymosin Beta-4 (Tβ4 residues 17–23, 889 g/mol); products sold under the name vary, and some contain or claim full-length Tβ4 (about 4,963 g/mol), so a vial’s COA mass is what identifies its contents (Delcourt et al. 2023; 2025). Full-length Tβ4 is a naturally occurring 43-amino-acid regulatory peptide implicated in actin sequestration, cell migration, and angiogenesis; G-actin sequestration is documented for the full-length protein, not for the fragment. The PCAC reviews TB-500 for wound healing. Orthopaedic and dermatologic compounding has been the primary historical use; the PMC12753158 orthopaedic review surveys preclinical and pilot human data.

Like BPC-157, TB-500 lacks any FDA-approved indication. Because products sold as TB-500 vary between the fragment and full-length Tβ4, identity and characterization are central questions in its 503A review. The FDA’s reviewers proposed not adding TB-500, but on July 23 the committee voted 8–6, with one abstention, to recommend it.

MOTS-c — Uses Under Review: Obesity and Osteoporosis

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of the mitochondrial genome. The PCAC docket evaluates two indications: obesity and osteoporosis. Preclinical work, including the mechanism paper indexed as PMID 41520850, links MOTS-c to AMPK activation, insulin sensitivity, and bone-cell signaling.

MOTS-c is in the same regulatory position as BPC-157 and TB-500, but its compounding history is shorter and the published human data thinner, which historically weighs against 503A inclusion. The FDA’s reviewers proposed not adding MOTS-c, but on July 23 the committee voted 7–5, with two abstentions, to recommend it for obesity and osteoporosis. A stable manufacturing and identity standard for the peptide is a further open question, since synthesis and storage parameters for mitochondrial-derived peptides remain less standardized than for traditional therapeutic peptides.

KPV (Lys-Pro-Val) — Uses Under Review: Wound Healing and Inflammatory Conditions

KPV is a tripeptide (Lys-Pro-Val) corresponding to the C-terminal tripeptide of α-MSH (alpha-melanocyte-stimulating hormone). Preclinical models describe anti-inflammatory effects in colitis and skin inflammation, and KPV has appeared in topical compounding for dermatologic and gastrointestinal applications. The PCAC reviews the indications of wound healing and inflammatory conditions.

As a short peptide, KPV is easier to characterize chemically than BPC-157 or TB-500, which works in its favour on the identity criterion. Whether the published efficacy and safety record is sufficient to support 503A inclusion remained the contested question: the FDA’s reviewers recommended against listing, but on July 23 the committee voted 8–6, with one abstention, to recommend KPV.

Day 2 — July 24, 2026: Semax, Epitalon, DSIP

Day 2 covers three peptides oriented around neurological and sleep-related indications. The compounding history concentrated in nootropic clinics and longevity-focused practices is the policy backdrop. The FDA’s reviewers recommended against listing all three; the committee’s July 24 votes, summarized by McDermott Will & Schulte, are given under each peptide below. All are advisory and non-binding.

Semax — Uses Under Review: Cerebral Ischemia, Migraine, Trigeminal Neuralgia

Semax is a heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-7) with an extended C-terminal proline-glycine-proline sequence. Originally developed in Russia, Semax has appeared in regional therapeutic use for cerebrovascular and neurological indications. The PCAC reviews cerebral ischemia, migraine, and trigeminal neuralgia — each evaluated for the free base and acetate forms.

The published clinical literature on Semax is predominantly Russian-language and dates from regional clinical practice rather than FDA-aligned trials. For a 503A bulks decision, the committee weighs whether that body of evidence meets the “recognized historical use in compounding” criterion under US conditions. On July 24 the committee voted 8–5, with one abstention, to recommend adding Semax.

Epitalon / Epithalon — Use Under Review: Insomnia

Epitalon (also spelled Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed in Russia and studied for its proposed effects on melatonin synthesis, telomerase activity, and pineal-gland signaling. The PCAC reviews the indication of insomnia, with the free base and acetate forms evaluated separately.

Epitalon’s research literature shares the Semax profile: a regional clinical and gerontology record concentrated in a small number of institutions, with limited replication in independent Western trials. The 503A decision is therefore about the strength of US compounding use plus identity and assay standards, not about pivotal trial efficacy. On July 24 the committee voted 7–4, with one abstention, to recommend adding Epitalon for insomnia.

DSIP / Emideltide — Uses Under Review: Opioid Withdrawal, Chronic Insomnia, Narcolepsy

DSIP (Delta Sleep-Inducing Peptide), referred to in the PCAC docket under the name Emideltide for the proposed compounded form, is a nonapeptide originally isolated from rabbit cerebral venous blood and named for its effect on EEG delta-wave activity. The PCAC reviews three indications: opioid withdrawal, chronic insomnia, and narcolepsy.

DSIP/Emideltide has the broadest indication slate of the seven peptides on the docket, and also one of the longest historical compounding records in the sleep and addiction-medicine niches. The breadth of indications cuts both ways: it gives the compounding side multiple use-history threads to point to, but it also gives the committee multiple efficacy questions to evaluate before voting on inclusion. On July 24 the committee voted 6–7, with one abstention, against adding emideltide — the only one of the seven peptides it did not recommend.

What “PCAC Review” Means in Practice

The PCAC vote is one step in a multi-stage regulatory cycle. The mechanical sequence is consistent across compounded peptide reviews:

1. FDA docket and meeting materials published in advance on the advisory committee calendar.
2. Public meeting — presentations by FDA staff, industry stakeholders, and clinicians; open comment period; committee deliberation; advisory vote on each candidate.
3. FDA review of PCAC recommendation — weeks to months, during which the agency drafts proposed rulemaking aligned with or departing from the committee’s advisory vote.
4. Federal Register proposed rule — the FDA’s formal position on inclusion or exclusion is published, opening a public comment window (typically 60 to 90 days).
5. Final rule — after comment review, the FDA publishes the binding determination. Inclusion or exclusion takes legal effect on the date the final rule is enforceable.

Inclusion on the 503A Bulks List allows licensed compounding pharmacies in the United States to use the peptide as an active pharmaceutical ingredient when preparing patient-specific prescriptions. The peptide remains unapproved as a finished drug — there is still no brand-name product on the US market — but the compounding pathway becomes available with documented sourcing and prescriber oversight. Exclusion blocks that pathway. The FDA Law Blog provides a useful primer on the broader 503A/503B compounding landscape at thefdalawblog.com, and OptiMantra covers the Category 2 shift context.

What Triggered This — The April 2026 Category 2 Removal

The July PCAC docket follows a concrete change. In April 2026, 12 peptides left Category 2 — the FDA’s interim list of bulk drug substances that may present significant safety risks in compounding — because the underlying nominations had been withdrawn: BPC-157, LL-37, DiHexa, DSIP, Epitalon, injectable GHK-Cu, KPV, PEG-MGF, Melanotan II, MOTS-c, Semax, and TB-500. The FDA’s Category 2 page, updated April 22, 2026, now lists them under “Bulk drug substances nominated but withdrawn”, still with their potential safety risks. Leaving Category 2 is not an approval, and it did not make these peptides compoundable: the FDA’s 503A category list of May 14, 2026 does not place any of them in Category 1 (GHK-Cu for non-injectable routes, a separate listing, is in Category 1), and none is on the 503A Bulks List.

A Federal Register notice on April 16, 2026 scheduled the July 23–24 PCAC meeting to consider seven of these peptides for affirmative inclusion on the 503A Bulks List: BPC-157, KPV, TB-500, MOTS-c, Emideltide (DSIP), Semax, and Epitalon. The notice is filed under 2026-07361 (Docket FDA-2025-N-6895), and Reuters reported the planned panel on April 15, 2026 at reuters.com. In short: leaving Category 2 changed how the FDA lists these peptides but granted no compounding status; the July meeting is the separate question of whether these compounds earn a place on the bulks list.

Separately, on April 1, 2026, the FDA reissued guidance reminding 503A and 503B compounders that the GLP-1 compounding-exemption conditions must now be met in full, given that semaglutide and tirzepatide have come off the shortage list and supply has stabilized. That reminder set the tone for the enforcement posture that followed through April and May.

The 503B Bulks Exclusion Proposal in Context

The PCAC peptide review does not happen in isolation. On April 30, 2026, the FDA proposed to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list — the parallel list governing outsourcing facilities that compound at scale — citing “no clinical need” now that the approved products are available and shortages have resolved. The proposal was published in the Federal Register on May 1, 2026 (notice 2026-08552); Reuters reported it at reuters.com. The proposed exclusion closes the compounded GLP-1 lane that expanded during the 2022 to 2024 shortage period.

The FDA’s own reviewers took a similarly cautious line at the July 23-24 PCAC review, recommending against listing all seven peptides. The committee went the other way on six of them, voting to recommend BPC-157, TB-500, MOTS-c, KPV, Semax, and Epitalon and voting down only DSIP / Emideltide; those votes are non-binding, and no final FDA action had been published as of October 7, 2026.

What This Means for Researchers and Clinics

For US compounding pharmacies and clinics, the practical takeaway is that the legal status of these seven peptides depends on whether and when the FDA acts on the July 2026 votes. Any change comes through Federal Register rulemaking, not the PCAC vote itself, but the vote is the leading indicator. Compounders that build protocols around BPC-157, TB-500, MOTS-c, KPV, Semax, Epitalon, or DSIP need to be tracking the rulemaking timeline now.

For US researchers studying these compounds in academic or industry-sponsored settings, the PCAC process does not directly govern preclinical or clinical research. Investigator-initiated trials and IND-enabled studies continue under their own framework. The bulks list is a compounding-supply question; the research lane is a separate regulatory track.

Research-use vs compounding context. Research-grade peptides remain available for in-vitro laboratory research use only — not for prescription, clinical, or human therapeutic use. US 503A and 503B determinations do not change research-use supply. A negative PCAC vote on, say, BPC-157 does not block laboratory study of the same compound under research-use compliance. A positive vote does not unlock US therapeutic use either — it only opens the 503A compounding pathway for patient-specific prescriptions. The frameworks operate independently.

For the broader UAE peptide landscape and how research-use compliance interacts with current GLP-1 and metabolic peptide research, see our peptide trends in the UAE 2026 analysis and the peptide legality guide for Dubai.